NTLA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
7.2M
-6.5%
7.7M
-49.1%
15.0M
-34.6%
23.0M
+67.0%
13.8M
Cost of Revenue
0
0
0
0
0
Gross Profit
7.2M
-6.5%
7.7M
-49.1%
15.0M
-34.6%
23.0M
+67.0%
13.8M
Operating Expenses
129.5M
+7.5%
120.4M
+4.2%
115.6M
-5.0%
121.7M
-2.8%
125.3M
R&D
83.3M
+0.9%
82.6M
+2.3%
80.7M
-8.9%
88.7M
-6.4%
94.7M
SG&A
46.1M
+22.0%
37.8M
+8.6%
34.8M
+5.3%
33.1M
+8.4%
30.5M
Operating Income
-122325000
-8.5%
-112760000
-12.2%
-100532000
-1.8%
-98710000
+11.5%
-111477000
EBITDA
-120402000
-8.8%
-110678000
-12.6%
-98330000
-2.1%
-96330000
+11.7%
-109062000
Net Income
-127485000
-19.6%
-106634000
-10.8%
-96231000
-0.5%
-95786000
+5.5%
-101324000
EPS (Basic)
$-0.91
-13.7%
$-0.80
+1.2%
$-0.81
+2.4%
$-0.83
+9.8%
$-0.92
EPS (Diluted)
$-0.91
-13.7%
$-0.80
+1.2%
$-0.81
+2.4%
$-0.83
+9.8%
$-0.92
Shares (Diluted)
140.2M
+5.0%
133.5M
+12.7%
118.5M
+2.1%
116.1M
+5.4%
110.2M
Intellia Therapeutics (NTLA) — Financials